Treatment is targeted on disease processes that are potentially reversible (e.g., active inflammation or vasoconstriction) and aims to minimise functional impairment of the patient. Definition Systemic sclerosis (SSc), also known as scleroderma, is a multi-system, autoimmune disease, characterised by ...
Objective To evaluate the effectiveness of the pharmacological treatments available for systemic sclerosis-associated interstitial lung disease (SSc-ILD) based on pulmonary function tests and radiologic findings. Materials and methods A systematic literature review and meta-analysis were conducted. A thorough...
Systemic sclerosisTreatmentDexamethasone pulse therapyA 22 year old female had for the last 8 years,, progressive tightness of the skin along with hyperpigmentation, Raynaud′s phenomenon, calcinosis cutis over bony prominences, dysphagia and pulmonary involvement. Treatment with 100 mg dexamethasone ...
Immunosuppressive treatment for systemic sclerosis – therapeutic challenges during the COVID pandemicCOVID-19 pandemicSYSTEMIC sclerodermaMEDICAL personnelCOVID-19SCLERODERMA (Disease)MIDDLE East respiratory syndromeDear Editor, Coronavirus disease 2019 (COVID-19), caused by a recently emerged member of the...
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as evi
Systemic sclerosis is a rare and often debilitating disorder characterized by a pathological triad: increased deposition of extracellular matrix and collagen in tissues, microvascular damage and dysfunction, and immune activation as evidenced by inflammation and frequent occurrence of autoantibodies. Until ...
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as evident from randomized clinical trials. Treatment...
K. et al. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res. Ther. 17, 213 (2015). PubMed PubMed Central Google Scholar Huang, J. et al. Nintedanib inhibits macrophage activation and ameliorates vascular and ...
1.Glucocorticoid combined with mycophenolate mofetil for treatment of 5 patients with systemic sclerosis accompanied by pulmonary hypertension;糖皮质激素加霉酚酸酯治疗系统性硬化症合并肺动脉高压5例 2.Clinical evaluation of EDTA in treatment of systemic sclerosis;依地酸钙钠治疗系统性硬化症86例 3.Objective...
Systemic sclerosis is an extremely variable disease in its manifestations and consequently, treatment needs to be individualized depending on the specific ... VD Steen - 《Current Opinion in Rheumatology》 被引量: 107发表: 1990年 Survival in systemic sclerosis-related pulmonary arterial hypertension in...